Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

196.94USD
20 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$196.94
Open
--
Day's High
--
Day's Low
--
Volume
35
Avg. Vol
1,188,566
52-wk High
$211.89
52-wk Low
$166.30

Latest Key Developments (Source: Significant Developments)

Toronto Innovation Acceleration Partners Announces Strategic Partnership With Amgen
Monday, 9 Sep 2019 

Sept 9 (Reuters) - Toronto Innovation Acceleration Partners::TIAP-AMGEN & TIAP WILL JOINTLY FUND NASCENT TECHNOLOGIES MANAGED BY TIAP ON BEHALF OF TORONTO-BASED MEMBER INSTITUTIONS .TORONTO INNOVATION ACCELERATION PARTNERS ANNOUNCES STRATEGIC PARTNERSHIP WITH AMGEN.TORONTO INNOVATION ACCELERATION PARTNERS SAYS UNDER TERMS, TIAP AND AMGEN WILL JOINTLY FUND NASCENT TECHNOLOGIES.  Full Article

Alexion Pharmaceuticals Says European Patent Office To Not Grant Co Patent Application Relating To Pharmaceutical Composition Of Soliris
Friday, 6 Sep 2019 

Sept 5 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION PHARMACEUTICALS - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF SOLIRIS (ECULIZUMAB).ALEXION PHARMACEUTICALS INC - WILL EVALUATE OPTION TO APPEAL THE EUROPEAN PATENT OFFICE’S DECISION.ALEXION PHARMA - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF MATTER OF SOLIRIS (ECULIZUMAB).  Full Article

Sanofi Says Court Rules In Favor Of Sanofi And Regeneron In Ongoing Praluent (Alirocumab) Patent Litigation
Thursday, 29 Aug 2019 

Aug 28 (Reuters) - Sanofi SA ::SANOFI : U.S. DISTRICT COURT INVALIDATES AMGEN PATENT CLAIMS TARGETING PCSK9.SANOFI - COURT RULES IN FAVOR OF SANOFI AND REGENERON IN ONGOING PRALUENT (ALIROCUMAB) PATENT LITIGATION.  Full Article

Amgen On Anticipated FTC Concerns Says Highly Confident About Deal For Otezla
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Amgen Inc ::AMGEN EXECUTIVE ON ANTICIPATED FTC CONCERNS SAYS HIGHLY CONFIDENT ABOUT DEAL FOR OTEZLA: CONF. CALL.  Full Article

Amgen Sets Quarterly Dividend Of $1.45per Share
Saturday, 3 Aug 2019 

Aug 2 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES 2019 THIRD QUARTER DIVIDEND.SETS QUARTERLY DIVIDEND OF $1.45PER SHARE.  Full Article

Amgen loses appeal against Coherus BioSciences over patent for purifying proteins
Monday, 29 Jul 2019 

July 29 (Reuters) - u.s. Appeals court upholds dismissal of amgen patent infringement lawsuit against coherus biosciences -- court ruling:.  Full Article

Amgen Says CHMP OF EMA Adopted Negative Opinion On MAA For Evenity
Friday, 28 Jun 2019 

June 28 (Reuters) - Amgen Inc ::AMGEN AND UCB PROVIDE REGULATORY UPDATE ON STATUS OF EVENITY™ (ROMOSOZUMAB) IN THE EU.AMGEN - CHMP OF EMA ADOPTED NEGATIVE OPINION ON MARKETING AUTHORIZATION APPLICATION FOR EVENITY (ROMOSOZUMAB) FOR TREATMENT OF SEVERE OSTEOPOROSIS.AMGEN INC - COMPANIES INTEND TO SUBMIT A WRITTEN NOTICE FOR A RE-EXAMINATION BY CHMP.AMGEN INC - "DISAPPOINTED" WITH CHMP OPINION AND BELIEVE THAT BODY OF EVIDENCE SUBMITTED SUPPORTS A "POSITIVE BENEFIT".AMGEN INC - CONTINUE TO BELIEVE THAT EVENITY HAS A POSITIVE BENEFIT OF RISK PROFILE.AMGEN INC - RE-EXAMINATION PROCESS GIVES COS OPPORTUNITY TO CLARIFY POSITION ON SUBMITTED DATA.  Full Article

Amgen Announces Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer
Wednesday, 29 May 2019 

May 29 (Reuters) - Amgen Inc ::AMGEN- RECOMMENDED PUBLIC CASH OFFER TO SHAREHOLDERS OF NUEVOLUTION AB TO TENDER ALL THEIR SHARES IN NUEVOLUTION TO AMGEN FOR SEK 32.50 PER SHARE IN CASH.  Full Article

Novartis' Sandoz unit defeats Amgen patent appeal related to white blood cell deficiency biosimilars
Wednesday, 8 May 2019 

May 8 (Reuters) - u.s. Appeals court rejects amgen appeal in patent litigation related to two novartis biosimilars -- court ruling:.  Full Article

Coherus Biosciences And Amgen Settle Trade Secrets Action
Friday, 3 May 2019 

May 2 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES AND AMGEN SETTLE TRADE SECRETS ACTION.COHERUS BIOSCIENCES - DETAILS OF SETTLEMENT ARE CONFIDENTIAL, COHERUS TO CONTINUE TO MARKET UDENYCA & PAY MID-SINGLE DIGIT ROYALTY TO AMGEN FOR 5 YEARS.COHERUS BIOSCIENCES - SETTLED TRADE SECRET ACTION BROUGHT BY AMGEN AGAINST COHERUS THAT WAS PENDING IN SUPERIOR COURT OF CALIFORNIA COUNTY OF VENTURA.  Full Article

Amgen drug shrinks lung cancer tumors in half of patients: study

An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial, the company said on Sunday.